

Supplementary Table S3: Summary of changes in immune cell subsets from baseline to Cycle 1 Day 8 after LY3022855 treatment

	MBC Patients		mCRPC Patients	
	<i>n</i>	Percentage change from baseline to Day 8 Median (IQR)	<i>n</i>	Percentage change from baseline to Day 8 Median (IQR)
C14+HLA-DR	12	-10 (-28 to -5)	10	-12 (-20 to -4)
Live cell count	18	-10 (-22 to 3)	11	-3 (-7 to 3)
CD3 count	18	-9 (-27 to 17)	11	9 (-8 to 18)
CD3 live cells	18	5 (-6 to 30)	11	3 (-11 to 15)
CD4+CD3	18	1 (-5 to 8)	11	0.5 (-1 to 4)
CD4 count	18	-5 (-31 to 14)	11	7 (-3 to 16)
CD8+CD3	18	-0.2 (-9 to 18)	11	-3 (-12 to 5)
CD8/CD4 ratio	18	-1 (-14 to 28)	11	-4 (-15 to 6)
CD8 count	18	-6 (-16 to 19)	11	12 (-13 to 22)
CD8/FOXP3 ratio	18	3 (-16 to 31)	11	-1 (-14 to 13)
CTLA4+CD4	18	-5 (-23 to 24)	11	21 (1 to 42)
TLA4+CD8	18	-16 (-29 to 36)	11	3 (-8 to 50)
FOXP3+CD4	18	-6 (-25 to 23)	11	9 (-13 to 17)
FOXP3+CD8	18	-3 (-49 to 17)	11	23 (11 to 61)
FOXP3 count	18	-7 (-41 to 29)	11	-0.1 (-13 to 24)
ICOS+CD4	18	-4 (-13 to 13)	11	22 (-3 to 47)
ICOS+CD8	18	-2 (-33 to 22)	11	-22 (-27 to 18)
KI67+CD4	18	-19 (-40 to 42)	11	1 (-16 to 81)
KI67+CD8	18	-6 (-48 to 31)	11	-4 (-22 to 66)
LAG3+CD4	18	17 (-23 to 84)	11	23 (12 to 59)
LAG3+CD8	18	27 (-20 to 84)	11	13 (-8 to 74)
PD1+CD4	18	5 (-10 to 16)	11	-9 (-23 to 19)
PD1+CD8	18	-8 (-16 to 21)	11	-8 (-21 to 23)
TIM3+CD4	18	-30 (-36 to -9)	11	-17 (-21 to -5)
TIM3+CD8	18	-3 (-12 to 18)	11	-17 (-31 to 19)

Abbreviations: IQR, inter-quartile range; MBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; *n*, participants with blood immune cell subset analyzed by flow cytometry.